Details for New Drug Application (NDA): 206210
✉ Email this page to a colleague
The generic ingredient in TOPIRAMATE is topiramate. There are twenty-six drug master file entries for this compound. Fifty-four suppliers are listed for this compound. Additional details are available on the topiramate profile page.
Summary for 206210
Tradename: | TOPIRAMATE |
Applicant: | Actavis Labs Fl |
Ingredient: | topiramate |
Patents: | 0 |
Pharmacology for NDA: 206210
Mechanism of Action | Cytochrome P450 2C19 Inhibitors Cytochrome P450 3A4 Inducers |
Physiological Effect | Decreased Central Nervous System Disorganized Electrical Activity |
Suppliers and Packaging for NDA: 206210
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
TOPIRAMATE | topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 206210 | ANDA | Teva Pharmaceuticals, Inc. | 0480-2356 | 0480-2356-01 | 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0480-2356-01) |
TOPIRAMATE | topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 206210 | ANDA | Teva Pharmaceuticals, Inc. | 0480-2356 | 0480-2356-56 | 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0480-2356-56) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE, EXTENDED RELEASE;ORAL | Strength | 25MG | ||||
Approval Date: | Mar 10, 2023 | TE: | AB1 | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE, EXTENDED RELEASE;ORAL | Strength | 50MG | ||||
Approval Date: | Mar 10, 2023 | TE: | AB1 | RLD: | No |
Profile for product number 003
Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE, EXTENDED RELEASE;ORAL | Strength | 100MG | ||||
Approval Date: | Mar 10, 2023 | TE: | AB1 | RLD: | No |
Complete Access Available with Subscription